Surgical management of abdominal and retroperitoneal Castleman's disease

Bucher, Pascal Alain Robert; Chassot, Gilles; Zufferey, Guillaume; Ris, Frédéric; Huber, Olivier; Morel, Philippe

doi:10.1186/1477-7819-3-33

Cited by 61 publications

(38 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[14]SpleenMAbdominal Pain, Fever, DiarrheaCTLymphoma, Splenic Hamartoma or AbscessCRP, ESRLaparoscopic Splenectomy7-cm HV Type7.Cecka F. [15]PancreasFEpigastric painCT, EUS, FNABGastric GIST, Pancreatic TumourNoneLaparoscopic Pancreatic Resection4-cm HV Type8.Martin A.K. [16]Right Retroperitoneal MassMNausea and VomitingEUS biopsy; CT-PetLymphoma, Metastatic Disease,Extra-Adrenal Pheocromocytoma, Testicular Cancer.NoneTotally Laparoscopic Resection5,5 cm HV Type9.Brusciano L. [17]Posterior Surface of Abdominal WallMPalpable MassCTNoneTotally Laparoscopic Resection5 cm PC Type10.Corcione F. [18]Lower Splenic PoleMRecurrent Palpitation and Vague Abdominal PainUS, CTAccessory spleenNoneTotally Laparoscopic Resection5-cm HV Type11.Otto M. [19]Right Adrenal GlandMNoneUS, CTAdrenal Gland, PheocromocytomaNoneLaparoscopic Adrenalectomy4,5 cm HV Type12.Rosado R. [20]InterAorto-Caval MassFAnemiaCT, FNABConverted Laparoscopy6.7-cm PC and HV Type F Famale, M Male; CT Computed Tomography, TVUS TransVaginal UltraSound, HV Hyaline-Vascular Type, HCC HepatoCellular Carcinoma, MRI Magnetic Resonance Imaging, PET Positron Emission Tomography, EGDS Esophago-Gastro-Duodenoscopy, SA Selective Angiography, PC Plasmacell Type, CRP C-Reaction Protein, ESR Erythrocyte Sedimentation Rate, EUS Endoscopic UltraSound, FNAB Fine Needle AgoBiopsy, US UltraSound …”

Section: Discussionmentioning

confidence: 99%

Laparoscopic treatment of abdominal unicentric castleman’s disease: a case report and literature review

et al. 2017

View full text Add to dashboard Cite

BackgroundCastleman’s disease is a rare lymphoproliferative disorder of unknown etiology that most commonly presents as a mediastinal nodal mass. It is exceptionally uncommon for Castleman’s disease to present in the mesentery and, only 53 cases have ever been described in the literature. Standard treatment for this lymphoproliferative disorder involving a single node is a complete “en bloc” surgical resection which has proven to be a curative approach in almost all cases without recurrence after 20 years of follow up. All 53 reported cases of mesenteric Castleman’s disease, except one, were treated with laparotomy.Case presentationWe report on a case of mesenteric Castleman’s disease localized in the mesentery which is the second reported case if its kind and was treated by a laparoscopic-assisted procedure. Our female patient had an uneventful postoperative course and was discharged in the 5th post-operative day. No signs of recurrence were present as evidenced by physical examination and total body CT scan 24 months after the operation. We compare our case with the other reported cases in which Castleman’s disease presented as an isolated mass in the abdomen.ConclusionAlthough a rare disease, Unicentric Castleman’s disease should always be considered when a solid asymptomatic abdominal mass is occasionally presented. The laparoscopic approach (LA) allows for the achievement of better results than open surgery, including a reduction in postoperative pain and length of hospital stay. In cases of masses of an uncertain nature, LA must be considered the last diagnostic tool and the first treatment one.

show abstract

Section: Discussionmentioning

confidence: 99%

Laparoscopic treatment of abdominal unicentric castleman’s disease: a case report and literature review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The most common location of CD is mediastinum (70%) but the involvement of extrathoracic sites like neck, axilla and pelvis have also been reported [4]. Retroperitoneal CD in the peripancreatic region is a rare entity [5], [6]. We report a case of the 34-year-old lady with suspected pancreatic neuroendocrine tumor diagnosed to have Castleman’s disease on histological examination of resected specimen.…”

Section: Introductionmentioning

confidence: 94%

Retroperitoneal unicentric Castleman’s disease: A case report

Abdessayed

Bdioui

Ammar

et al. 2017

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

show abstract

“…Therefore, depending on the location of the tumor, patients with large tumors may present chest discomfort or pain, dyspnea, cough, haemoptysis, abdominal or back pain, discomfort, urinary obstruction due to ureteral compression which may lead to a renal colic, bowel compression, sub-occlusive intestinal syndrome or icterus [9,26,27]. Patients with UCD have good prognosis, the gold standard treatment being complete surgical excision, which has proven over the years to be the curative treatment for this pathology as it is for other type of tumors [28][29][30]. For patients with well-vascularized large tumors, preoperative angiography with selective embolization should be performed in order to reduce the bleeding risk.…”

Section: Clinical Aspectsmentioning

confidence: 99%

Castleman�s Disease - Clinical, Histological and Therapeutic Features

Marcu¹,

Spînu²,

Socea³

et al. 2018

Rev. Chim.

View full text Add to dashboard Cite

Castleman�s disease (CD) is a rare and benign lymphoproliferative pathology, characterized by lymphoid tissue hyperplasia, process that can occur at any site of the lymphoid chain. The purpose of this paper is to review the existing data regarding Castleman�s disease etiopathogenesis and treatment. Considering the extent of the lymphoid tissue involvement Castleman�s disease can be classified as unicentric (UCD) and multicentric (MCD). Another classification of this pathology is based on the histopathological features: hyaline vascular CD (90% of cases), plasma cell CD (less than 10%) and mixed cell type. Patients with UCD have good prognosis, the gold standard treatment being complete surgical excision. The multicentric type in contrast to UCD has a worse prognosis and associates the risk of evolving to lymphoma. Over the years different therapeutic strategies have been applied in the management of multicentric Castleman�s disease: glucocorticoids, chemotherapy, antiviral agents and monoclonal antibodies that target CD (cluster of differentiation) 20, interleukin -6 (IL-6) and IL-6 receptors. Castleman�s disease is a rare and complex pathology, whose etiopathogenesis is still incompletely elucidated. In the past few years the overall survival and progression free survival has significantly increased, due to different therapeutic options that have emerged, options that have constantly offered better and better results. Further investigation regarding the chemical interactions between different receptors and therapeutic molecules, understanding the mechanism of action and the potential benefits of each therapeutic agent may prove useful in clinical practice for treating CD.

show abstract

Surgical management of abdominal and retroperitoneal Castleman's disease

Cited by 61 publications

References 61 publications

Laparoscopic treatment of abdominal unicentric castleman’s disease: a case report and literature review

Laparoscopic treatment of abdominal unicentric castleman’s disease: a case report and literature review

Retroperitoneal unicentric Castleman’s disease: A case report

Castleman�s Disease - Clinical, Histological and Therapeutic Features

Contact Info

Product

Resources

About